Skip to content
Head to head

Cronos Group vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: CRON · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

CRON +25.6%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
CRONTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price3.0421.77
Change today-1.30%+1.68%
1-year return+32.2%+57.5%
Market cap$1.11B$69.76B
52-week range2.35 – 3.9113.92 – 22.07
Valuation
P/E (TTM)19.00311.00
P/E percentile, own 5-yr range88th100th
P/B1.041.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.02-0.30
Net profit (TTM)$-7.33M$-970.94M
Revenue (TTM)$206.20M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+74.6%+6.7%
Gross margin46.6%65.8%
Operating margin4.2%14.3%
Net margin28.0%0.9%
Free cash flow (TTM)$65.10M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership58.3%51.3%
Insider activity (12mo)35 buy / 15 sell19 buy / 31 sell
Short interest (% of float)1.1%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$5 (+61%)$50 (+132%)
StockVane view
StockVane Quant RatingC (74)C (90)
Company
Employees61047,029
Founded20121781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.